8-K: Lifecore Acquired by Webster Equity Partners

Lifecore Biomedical, Inc. has entered into a definitive agreement to be acquired by an affiliate of Webster Equity Partners for $6.28 per share in cash, plus contingent value rights.

Summary

• Lifecore Biomedical, Inc. has entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Partners.
• The transaction values Lifecore at up to approximately $663.7 million, assuming full achievement of performance milestones.
• Common stockholders will receive $6.28 per share in cash at closing, plus a contingent value right (CVR) per share.
• Series A Preferred Stockholders will receive the Conversion Amount in cash at closing, plus a CVR per share.
• The CVRs represent the right to potential future cash payments of up to $160 million in aggregate, contingent upon Lifecore achieving performance milestones in 2028, 2029, and 2030.
• The transaction is expected to close at the end of the fourth quarter of 2026, subject to stockholder and regulatory approvals.
• Lifecore will become a privately held company, and its common stock will no longer be listed on any stock exchange.
• The company expects to continue operating under the Lifecore name and brand, maintaining its headquarters in Chaska, Minnesota.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating a strategic move to enhance growth and shareholder value through acquisition by experienced investors.

Positives

• Immediate and compelling value for stockholders with a 49.5% premium to the closing price on September 25, 2026, for the cash component.
• Potential for up to $9.67 per common equivalent share in combined cash and CVRs at full performance milestone achievement, representing a 130.2% premium.
• Acquisition by experienced healthcare investors (Webster Equity Partners) with a focus on growth and operational support.
• Contingent Value Rights (CVRs) provide stockholders with an opportunity to share in future success based on performance milestones.
• Commitment to maintain Lifecore's headquarters in Chaska, Minnesota, and continue operating under the Lifecore name and brand.
• The transaction is expected to support Lifecore's growth objectives and accelerate its next phase of development.
• A three-year extension to the Manufacturing Agreement with Alcon, running through 2034, was also announced, demonstrating continued commercial strength.

Negatives

• Lifecore will cease to be a publicly traded company, meaning its common stock will be delisted from the Nasdaq Stock Market.
• The value of the CVRs is contingent and uncertain, with no guarantee of full payment or any payment at all.
• The transaction is subject to closing conditions, including stockholder and regulatory approvals, which may not be met.
• Potential for increased scrutiny and distraction during the go-shop period and until closing.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to satisfy closing conditions, including stockholder and regulatory approvals.
• The value to stockholders from the contingent value rights (CVRs) is uncertain and holders may receive less-than-anticipated payments or no payments.
• The announcement and pendency of the transaction could adversely affect Lifecore's ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, and stockholders.
• Risks related to the diversion of management's attention from ongoing business operations.
• Potential litigation relating to the proposed transaction.
• Certain restrictions during the pendency of the transaction may impact Lifecore's ability to make changes in its business or pursue certain business opportunities.

Future Outlook

The company anticipates continued operation under the Lifecore name and brand as a privately held entity, with expectations of accelerated growth supported by Webster Equity Partners' resources and expertise. The achievement of specific revenue and EBITDA milestones in 2028-2030 will determine the payout of contingent value rights.

Management Comments

• We are thrilled to announce this exciting transaction which we believe will support Lifecores next phase of growth.
• Lifecore is approaching an exciting inflection point, with the potential for numerous programs to commercialize by the end of 2028.
• For our stockholders, this transaction delivers immediate and compelling value and is a testament to the contributions of the many stakeholders whose support, dedication, and hard work made this agreement possible.
• Our number one business priority is our customers and providing them with the exceptional technical expertise, quality, and service that are the hallmarks of Lifecores business.
• By doing so, we will maintain the momentum we are building and continue it into our next chapter.

Industry Context

StockSavvy.ai notes that this acquisition aligns with a broader trend of private equity firms investing in specialized CDMOs within the healthcare and pharmaceutical sectors, seeking to leverage their expertise and capital to drive growth and operational efficiencies.

Comparison to Industry Standards

• The acquisition price of $6.28 per share, representing a 49.5% premium, is competitive for a CDMO in the sterile injectable space, reflecting the company's specialized capabilities.
• The inclusion of CVRs is a common mechanism in such transactions to bridge valuation gaps and incentivize future performance, aligning seller and buyer interests.
• The focus on sterile injectable pharmaceutical products and complex formulations places Lifecore in a high-demand segment of the pharmaceutical services market.

Legal Proceedings

• The filing mentions potential litigation related to the proposed transaction.
• Specific litigation matters involving Ardeshir Haerizadeh and 22NW Fund, L.P. are referenced in the CVR agreement and EBITDA calculation details, but are not directly related to the merger announcement itself.

Related Party Transactions

• The Voting and Support Agreements were entered into with stockholders affiliated with directors Nelson Obus (Wynnefield Stockholders) and Christopher S. Kiper (Legion Stockholders), who have agreed to vote their shares in favor of the merger.

Stakeholder Impact

• Shareholders will receive $6.28 per share in cash at closing, plus CVRs, providing immediate value and potential future upside.
• Employees are assured of no organizational changes between signing and closing, with continued operation under the Lifecore name and brand, and maintenance of benefits.
• Customers and suppliers are expected to experience continuity in operations and business relationships.

Next Steps

• Lifecore stockholders will vote on the merger agreement.
• Regulatory approvals must be obtained.
• The transaction is expected to close at the end of Q4 2026.
• A go-shop period will allow Lifecore to solicit superior acquisition proposals for 30 days.

Key Dates

Recommendation

The offer provides a significant premium and a path to liquidity, but the CVRs introduce uncertainty. For existing shareholders, holding allows participation in the potential upside from CVRs while benefiting from the immediate cash component. However, the delisting and private ownership structure may not appeal to all investors, making 'hold' a prudent recommendation pending further details on post-closing operations and CVR realization.

Keywords

Merger Agreement, Acquisition, Webster Equity Partners, Contingent Value Rights, CDMO, Sterile Injectable Pharmaceuticals, Hyaluronic Acid, Go-Shop Period